

European Journal of Pharmaceutics and Biopharmaceutics 54 (2002) 255

EUPOPean

Journal of

Pharmaceudics and

Biopharmacoudics

www.elsevier.com/locate/ejphabio

Corrigendum

Corrigendum to "Variability in cimetidine absorption and plasma double peaks following oral administration in the fasted state in humans: correlation with antral gastric motility"

[Eur. J. Pharm. Biopharm. 53 (2002) 37–47] **

Narushi Takamatsu^a, Lynda S. Welage^b, Yayoi Hayashi^c, Ryuzo Yamamoto^d, Jeffrey L. Barnett^e, Vinod P. Shah^{f,1}, Lawrence J. Lesko^{f,1}, Chandrasekharan Ramachandran^b, Gordon L. Amidon^{b,*}

^aYamanouchi Pharmaceutical Co. Ltd., Shizuoka, Japan

^bCollege of Pharmacy, The University of Michigan, Ann Arbor, MI, USA

^cNagoya City University, Aichi, Japan

^dOno Phamaceutical Co. Ltd., Osaka, Japan

^cDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA

^fFood and Drug Administration, Rockville, MD, USA

The authors of the above paper would like to correct the following typographical errors in the publication.

In Materials and Methods section 2.2 Study protocol:

Page 39, column 1, 2nd paragraph should read

Treatment regimen 1 (Quiescent p.o.): Cimetidine 300 mg solution (Tagamet oral solution, 300 mg/5 ml) was administered orally during early phase I of MMC (quiescent phase) with **200** ml of water. Early phase I of MMC was defined as 15 min following the end of phase III.

Page 39, column 1, 3rd paragraph should read

Treatment regimen 2 (Active p.o.): Cimetidine 300 mg solution was administered orally at the initiation of phase II (active phase) with **200** ml of water.

Page 39, column 1, 4th paragraph should read

Treatment regimen 3 (Active i.v.): Cimetidine 300 mg solution (Tagamet injection, 300 mg/2 ml) was infused intravenously for 10 min with an infusion pump at the initiation of phase II (active phase). At the start of the infusion the subject was given **200** ml of water to drink.

The three errors deal with the actual volume of water administered in the treatment regimes. Thus, in treatment regimes 1 and 2 the volume of water administered should be 200 ml instead of 20 ml and in treatment regime 3, it should be 200 ml instead of 25 ml. The authors sincerely apologize for this oversight and regret any possible confusion caused.

[★] PII of original article: S0939-6411(01)00207-7

^{*} Corresponding author. College of Pharmacy, The University of Michigan, 428 Church Street, Ann Arbor, MI 48109, USA. Tel.: +1-734-764-2440; fax: +1.734-763-6432

E-mail address: glamidon@umich.edu (G.L. Amidon).

¹ This paper represents the personal opinions of the author and does not necessarily represent the views or policies of the Agency.